Studying memory and thinking problems in older Chinese adults, including Parkinson's disease
Follows Chinese patients with cognitive impairment to understand how it develops and progresses.
Plain-language title generated from the registry record
Registry title: China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration
Key facts
- Where
- Yantai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Source: NCT07586501, who can take part
Where in China
- Yantai Yuhuangding HospitalYantai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yantai Yuhuangding Hospital
- Trial code
- NCT07586501
- Record updated
- 14 May 2026
- Original description
This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.Read full original descriptionShow less
China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration
This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia.
Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance.
Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.
Inclusion: Participants with clinically diagnosed cognitive impairment. Patients with clinically diagnosed Parkinson's disease. Healthy control participants.
Exclusion: Central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders; Malignant tumors. Family history of genetic disorders.